Global Neurodegenerative Diseases Market
Global Neurodegenerative Diseases Market

Neurodegenerative Diseases Comprehensive Study by Application (Alzheimer's Disease, Huntington Disease, Parkinson's Disease, Amyotrophic Lateral Sclerosis), Drug Type (N-methyl-D-aspartate Receptor, Dopamine Inhibitors, Selective Serotonin Reuptake Inhibitor, Other Drug) Players and Region - Global Market Outlook to 2024

Neurodegenerative Diseases Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024  

Sep 2019 Edition 202 Pages 210 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Neurodegenerative Diseases Market Overview:
The brain is a complex organ with a vast number of the pathway that allows doing different activities. Brain is made up of billions of cells which are responsible for every second of everyday proper functioning. Some of the most important cells in the brain are called neurons. Neuron communicates with each other to perform every function of brain whether it involves movement, thinking, talking or remembering of things. When the cell of the brain are closely connected and miscommunicated in one area, it disrupts the other brain activities and leads to disease. Neurodegenerative disease is a term for a range of condition which primarily affects the neurons in the human brain. It occurs when the nerve cell in the brain or peripheral nervous system lose function over time and dies. These diseases are incurable and cause problems with movement or mental functioning (called dementias). The risk of this is being affected by the disease increases with age. Neurodegenerative diseases include Alzheimer's, multiple sclerosis, Huntington's disease, Parkinson's disease, multiple system atrophy, spinal muscular atrophy, and others. Change in lifestyles such as unhealthy eating habits, improper sleeping, and high-stress levels are likely to result in degenerative of nerve cells. Some of the key players profiled in the study are Novartis (Switzerland), Merck Serono (United States), Teva Pharmaceutical (Isreal), Pfizer (United States), Biogen Idec (United States), Bayer Schering Pharma AG (Germany), Boehringer Ingelheim (Germany), Amarin Corporation (Ireland), AstraZeneca (United Kingdom), Alector (United States), Yumanity Therapeutics (United States), Yangtze River Pharmaceutical Group (China) and Chongqing Zein Pharmaceutical (China).

On the basis of geography, the market of Neurodegenerative Diseases has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Drug Type, the sub-segment i.e. N-methyl-D-aspartate Receptor will boost the Neurodegenerative Diseases market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Rising Prevalence of Neurological Disorder among All Genders, Races and Geographical Backgrounds
  • Increased Focus in Patient-Centric Healthcare Delivery
  • Growing Awareness about Neurodegenerative Diseases

Market Trend
  • Innovation in Neurodegenerative Disease Drug Discovery
  • Remote Monitoring and Growing Focus on Consumer-Centric Mobility Solutions

Restraints
  • Stringent Government Rules and Regulations
  • High Cost Associated With Neurodegenerative Disease
  • Patent Expiry of Neurodegenerative Disease Treatment Products

Opportunities
  • Rising Incidence Due To Change In Lifestyle Such As Improper Sleeping, High-Stress Levels, And Unhealthy Eating Habits

Challenges
  • Dearth of Skilled Professionals to Treat Neurodegenerative Diseases


According to the study of Parkinsonís Association in 2018, around 1.2 million people in the U.S are estimated to be suffering from Parkinsonís disease by 2030. As per the Alzheimerís Association, around 5.4 million Americans were suffering from Alzheimerís in the year 2016. Moreover, this disease is more prevalent among people aged 65 years and above.


Target Audience:
Medical Institutes, Industry Association Related to Neurodegenerative Diseases, Government Regulatory Bodies, Government and Private Research Organization and Others

Major Objectives Focused through this Study
• To define, describe, and forecast the Global Neurodegenerative Diseases market on the basis of product [] , application [Alzheimer's Disease, Huntington Disease, Parkinson's Disease and Amyotrophic Lateral Sclerosis], key regions and end user
• To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
• To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
• Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
• To provide market size for various segments of the Neurodegenerative Diseases market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
• To strategically profile the key players and analyzing their market shares and core competencies in the Neurodegenerative Diseases industry
• To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are Eisai (Japan), H.Lundbeck A/S (Denmark) and Jiangsu Hansoh Pharmaceutical (China).
** Confirmation on availability of data would be informed prior purchase

While framing the research framework, major and emerging players operating in the Neurodegenerative Diseases market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. Top-down and bottom-up approaches have been used to determine the overall market size. Sizes of the other individual markets have been estimated using the percentage splits obtained through secondary sources such as Hoovers, Bloomberg BusinessWeek, and Dow Jones (Factiva), along with primary respondents. The complete methodology includes the study of the annual and financial reports of the key market players and extensive interviews with industry experts such as CEOs, VPs, directors, and marketing executives for key insights (both qualitative and quantitative) related to the market.
Report Objectives / Segmentation Covered
By Application
  • Alzheimer's Disease
  • Huntington Disease
  • Parkinson's Disease
  • Amyotrophic Lateral Sclerosis
By Drug Type
  • N-methyl-D-aspartate Receptor
  • Dopamine Inhibitors
  • Selective Serotonin Reuptake Inhibitor
  • Other Drug

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence of Neurological Disorder among All Genders, Races and Geographical Backgrounds
      • 3.2.2. Increased Focus in Patient-Centric Healthcare Delivery
      • 3.2.3. Growing Awareness about Neurodegenerative Diseases
    • 3.3. Market Challenges
      • 3.3.1. Dearth of Skilled Professionals to Treat Neurodegenerative Diseases
    • 3.4. Market Trends
      • 3.4.1. Innovation in Neurodegenerative Disease Drug Discovery
      • 3.4.2. Remote Monitoring and Growing Focus on Consumer-Centric Mobility Solutions
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Neurodegenerative Diseases, by Application, Drug Type and Region (value) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Neurodegenerative Diseases (Value)
      • 5.2.1. Global Neurodegenerative Diseases by: Application (Value)
        • 5.2.1.1. Alzheimer's Disease
        • 5.2.1.2. Huntington Disease
        • 5.2.1.3. Parkinson's Disease
        • 5.2.1.4. Amyotrophic Lateral Sclerosis
      • 5.2.2. Global Neurodegenerative Diseases by: Drug Type (Value)
        • 5.2.2.1. N-methyl-D-aspartate Receptor
        • 5.2.2.2. Dopamine Inhibitors
        • 5.2.2.3. Selective Serotonin Reuptake Inhibitor
        • 5.2.2.4. Other Drug
      • 5.2.3. Global Neurodegenerative Diseases Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Neurodegenerative Diseases: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novartis (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Merck Serono (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Teva Pharmaceutical (Isreal)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Biogen Idec (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bayer Schering Pharma AG (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Boehringer Ingelheim (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Amarin Corporation (Ireland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. AstraZeneca (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Alector (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Yumanity Therapeutics (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Yangtze River Pharmaceutical Group (China)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Chongqing Zein Pharmaceutical (China)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
  • 7. Global Neurodegenerative Diseases Sale, by Application, Drug Type and Region (value) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Neurodegenerative Diseases (Value)
      • 7.2.1. Global Neurodegenerative Diseases by: Application (Value)
        • 7.2.1.1. Alzheimer's Disease
        • 7.2.1.2. Huntington Disease
        • 7.2.1.3. Parkinson's Disease
        • 7.2.1.4. Amyotrophic Lateral Sclerosis
      • 7.2.2. Global Neurodegenerative Diseases by: Drug Type (Value)
        • 7.2.2.1. N-methyl-D-aspartate Receptor
        • 7.2.2.2. Dopamine Inhibitors
        • 7.2.2.3. Selective Serotonin Reuptake Inhibitor
        • 7.2.2.4. Other Drug
      • 7.2.3. Global Neurodegenerative Diseases Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Neurodegenerative Diseases: by Application(USD Million)
  • Table 2. Neurodegenerative Diseases Alzheimer's Disease , by Region USD Million (2013-2018)
  • Table 3. Neurodegenerative Diseases Huntington Disease , by Region USD Million (2013-2018)
  • Table 4. Neurodegenerative Diseases Parkinson's Disease , by Region USD Million (2013-2018)
  • Table 5. Neurodegenerative Diseases Amyotrophic Lateral Sclerosis , by Region USD Million (2013-2018)
  • Table 6. Neurodegenerative Diseases: by Drug Type(USD Million)
  • Table 7. Neurodegenerative Diseases N-methyl-D-aspartate Receptor , by Region USD Million (2013-2018)
  • Table 8. Neurodegenerative Diseases Dopamine Inhibitors , by Region USD Million (2013-2018)
  • Table 9. Neurodegenerative Diseases Selective Serotonin Reuptake Inhibitor , by Region USD Million (2013-2018)
  • Table 10. Neurodegenerative Diseases Other Drug , by Region USD Million (2013-2018)
  • Table 11. South America Neurodegenerative Diseases, by Country USD Million (2013-2018)
  • Table 12. South America Neurodegenerative Diseases, by Application USD Million (2013-2018)
  • Table 13. South America Neurodegenerative Diseases, by Drug Type USD Million (2013-2018)
  • Table 14. Brazil Neurodegenerative Diseases, by Application USD Million (2013-2018)
  • Table 15. Brazil Neurodegenerative Diseases, by Drug Type USD Million (2013-2018)
  • Table 16. Argentina Neurodegenerative Diseases, by Application USD Million (2013-2018)
  • Table 17. Argentina Neurodegenerative Diseases, by Drug Type USD Million (2013-2018)
  • Table 18. Rest of South America Neurodegenerative Diseases, by Application USD Million (2013-2018)
  • Table 19. Rest of South America Neurodegenerative Diseases, by Drug Type USD Million (2013-2018)
  • Table 20. Asia Pacific Neurodegenerative Diseases, by Country USD Million (2013-2018)
  • Table 21. Asia Pacific Neurodegenerative Diseases, by Application USD Million (2013-2018)
  • Table 22. Asia Pacific Neurodegenerative Diseases, by Drug Type USD Million (2013-2018)
  • Table 23. China Neurodegenerative Diseases, by Application USD Million (2013-2018)
  • Table 24. China Neurodegenerative Diseases, by Drug Type USD Million (2013-2018)
  • Table 25. Japan Neurodegenerative Diseases, by Application USD Million (2013-2018)
  • Table 26. Japan Neurodegenerative Diseases, by Drug Type USD Million (2013-2018)
  • Table 27. India Neurodegenerative Diseases, by Application USD Million (2013-2018)
  • Table 28. India Neurodegenerative Diseases, by Drug Type USD Million (2013-2018)
  • Table 29. South Korea Neurodegenerative Diseases, by Application USD Million (2013-2018)
  • Table 30. South Korea Neurodegenerative Diseases, by Drug Type USD Million (2013-2018)
  • Table 31. Taiwan Neurodegenerative Diseases, by Application USD Million (2013-2018)
  • Table 32. Taiwan Neurodegenerative Diseases, by Drug Type USD Million (2013-2018)
  • Table 33. Australia Neurodegenerative Diseases, by Application USD Million (2013-2018)
  • Table 34. Australia Neurodegenerative Diseases, by Drug Type USD Million (2013-2018)
  • Table 35. Rest of Asia-Pacific Neurodegenerative Diseases, by Application USD Million (2013-2018)
  • Table 36. Rest of Asia-Pacific Neurodegenerative Diseases, by Drug Type USD Million (2013-2018)
  • Table 37. Europe Neurodegenerative Diseases, by Country USD Million (2013-2018)
  • Table 38. Europe Neurodegenerative Diseases, by Application USD Million (2013-2018)
  • Table 39. Europe Neurodegenerative Diseases, by Drug Type USD Million (2013-2018)
  • Table 40. Germany Neurodegenerative Diseases, by Application USD Million (2013-2018)
  • Table 41. Germany Neurodegenerative Diseases, by Drug Type USD Million (2013-2018)
  • Table 42. France Neurodegenerative Diseases, by Application USD Million (2013-2018)
  • Table 43. France Neurodegenerative Diseases, by Drug Type USD Million (2013-2018)
  • Table 44. Italy Neurodegenerative Diseases, by Application USD Million (2013-2018)
  • Table 45. Italy Neurodegenerative Diseases, by Drug Type USD Million (2013-2018)
  • Table 46. United Kingdom Neurodegenerative Diseases, by Application USD Million (2013-2018)
  • Table 47. United Kingdom Neurodegenerative Diseases, by Drug Type USD Million (2013-2018)
  • Table 48. Netherlands Neurodegenerative Diseases, by Application USD Million (2013-2018)
  • Table 49. Netherlands Neurodegenerative Diseases, by Drug Type USD Million (2013-2018)
  • Table 50. Rest of Europe Neurodegenerative Diseases, by Application USD Million (2013-2018)
  • Table 51. Rest of Europe Neurodegenerative Diseases, by Drug Type USD Million (2013-2018)
  • Table 52. MEA Neurodegenerative Diseases, by Country USD Million (2013-2018)
  • Table 53. MEA Neurodegenerative Diseases, by Application USD Million (2013-2018)
  • Table 54. MEA Neurodegenerative Diseases, by Drug Type USD Million (2013-2018)
  • Table 55. Middle East Neurodegenerative Diseases, by Application USD Million (2013-2018)
  • Table 56. Middle East Neurodegenerative Diseases, by Drug Type USD Million (2013-2018)
  • Table 57. Africa Neurodegenerative Diseases, by Application USD Million (2013-2018)
  • Table 58. Africa Neurodegenerative Diseases, by Drug Type USD Million (2013-2018)
  • Table 59. North America Neurodegenerative Diseases, by Country USD Million (2013-2018)
  • Table 60. North America Neurodegenerative Diseases, by Application USD Million (2013-2018)
  • Table 61. North America Neurodegenerative Diseases, by Drug Type USD Million (2013-2018)
  • Table 62. United States Neurodegenerative Diseases, by Application USD Million (2013-2018)
  • Table 63. United States Neurodegenerative Diseases, by Drug Type USD Million (2013-2018)
  • Table 64. Canada Neurodegenerative Diseases, by Application USD Million (2013-2018)
  • Table 65. Canada Neurodegenerative Diseases, by Drug Type USD Million (2013-2018)
  • Table 66. Mexico Neurodegenerative Diseases, by Application USD Million (2013-2018)
  • Table 67. Mexico Neurodegenerative Diseases, by Drug Type USD Million (2013-2018)
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Company Basic Information, Sales Area and Its Competitors
  • Table 79. Company Basic Information, Sales Area and Its Competitors
  • Table 80. Company Basic Information, Sales Area and Its Competitors
  • Table 81. Neurodegenerative Diseases: by Application(USD Million)
  • Table 82. Neurodegenerative Diseases Alzheimer's Disease , by Region USD Million (2019-2024)
  • Table 83. Neurodegenerative Diseases Huntington Disease , by Region USD Million (2019-2024)
  • Table 84. Neurodegenerative Diseases Parkinson's Disease , by Region USD Million (2019-2024)
  • Table 85. Neurodegenerative Diseases Amyotrophic Lateral Sclerosis , by Region USD Million (2019-2024)
  • Table 86. Neurodegenerative Diseases: by Drug Type(USD Million)
  • Table 87. Neurodegenerative Diseases N-methyl-D-aspartate Receptor , by Region USD Million (2019-2024)
  • Table 88. Neurodegenerative Diseases Dopamine Inhibitors , by Region USD Million (2019-2024)
  • Table 89. Neurodegenerative Diseases Selective Serotonin Reuptake Inhibitor , by Region USD Million (2019-2024)
  • Table 90. Neurodegenerative Diseases Other Drug , by Region USD Million (2019-2024)
  • Table 91. South America Neurodegenerative Diseases, by Country USD Million (2019-2024)
  • Table 92. South America Neurodegenerative Diseases, by Application USD Million (2019-2024)
  • Table 93. South America Neurodegenerative Diseases, by Drug Type USD Million (2019-2024)
  • Table 94. Brazil Neurodegenerative Diseases, by Application USD Million (2019-2024)
  • Table 95. Brazil Neurodegenerative Diseases, by Drug Type USD Million (2019-2024)
  • Table 96. Argentina Neurodegenerative Diseases, by Application USD Million (2019-2024)
  • Table 97. Argentina Neurodegenerative Diseases, by Drug Type USD Million (2019-2024)
  • Table 98. Rest of South America Neurodegenerative Diseases, by Application USD Million (2019-2024)
  • Table 99. Rest of South America Neurodegenerative Diseases, by Drug Type USD Million (2019-2024)
  • Table 100. Asia Pacific Neurodegenerative Diseases, by Country USD Million (2019-2024)
  • Table 101. Asia Pacific Neurodegenerative Diseases, by Application USD Million (2019-2024)
  • Table 102. Asia Pacific Neurodegenerative Diseases, by Drug Type USD Million (2019-2024)
  • Table 103. China Neurodegenerative Diseases, by Application USD Million (2019-2024)
  • Table 104. China Neurodegenerative Diseases, by Drug Type USD Million (2019-2024)
  • Table 105. Japan Neurodegenerative Diseases, by Application USD Million (2019-2024)
  • Table 106. Japan Neurodegenerative Diseases, by Drug Type USD Million (2019-2024)
  • Table 107. India Neurodegenerative Diseases, by Application USD Million (2019-2024)
  • Table 108. India Neurodegenerative Diseases, by Drug Type USD Million (2019-2024)
  • Table 109. South Korea Neurodegenerative Diseases, by Application USD Million (2019-2024)
  • Table 110. South Korea Neurodegenerative Diseases, by Drug Type USD Million (2019-2024)
  • Table 111. Taiwan Neurodegenerative Diseases, by Application USD Million (2019-2024)
  • Table 112. Taiwan Neurodegenerative Diseases, by Drug Type USD Million (2019-2024)
  • Table 113. Australia Neurodegenerative Diseases, by Application USD Million (2019-2024)
  • Table 114. Australia Neurodegenerative Diseases, by Drug Type USD Million (2019-2024)
  • Table 115. Rest of Asia-Pacific Neurodegenerative Diseases, by Application USD Million (2019-2024)
  • Table 116. Rest of Asia-Pacific Neurodegenerative Diseases, by Drug Type USD Million (2019-2024)
  • Table 117. Europe Neurodegenerative Diseases, by Country USD Million (2019-2024)
  • Table 118. Europe Neurodegenerative Diseases, by Application USD Million (2019-2024)
  • Table 119. Europe Neurodegenerative Diseases, by Drug Type USD Million (2019-2024)
  • Table 120. Germany Neurodegenerative Diseases, by Application USD Million (2019-2024)
  • Table 121. Germany Neurodegenerative Diseases, by Drug Type USD Million (2019-2024)
  • Table 122. France Neurodegenerative Diseases, by Application USD Million (2019-2024)
  • Table 123. France Neurodegenerative Diseases, by Drug Type USD Million (2019-2024)
  • Table 124. Italy Neurodegenerative Diseases, by Application USD Million (2019-2024)
  • Table 125. Italy Neurodegenerative Diseases, by Drug Type USD Million (2019-2024)
  • Table 126. United Kingdom Neurodegenerative Diseases, by Application USD Million (2019-2024)
  • Table 127. United Kingdom Neurodegenerative Diseases, by Drug Type USD Million (2019-2024)
  • Table 128. Netherlands Neurodegenerative Diseases, by Application USD Million (2019-2024)
  • Table 129. Netherlands Neurodegenerative Diseases, by Drug Type USD Million (2019-2024)
  • Table 130. Rest of Europe Neurodegenerative Diseases, by Application USD Million (2019-2024)
  • Table 131. Rest of Europe Neurodegenerative Diseases, by Drug Type USD Million (2019-2024)
  • Table 132. MEA Neurodegenerative Diseases, by Country USD Million (2019-2024)
  • Table 133. MEA Neurodegenerative Diseases, by Application USD Million (2019-2024)
  • Table 134. MEA Neurodegenerative Diseases, by Drug Type USD Million (2019-2024)
  • Table 135. Middle East Neurodegenerative Diseases, by Application USD Million (2019-2024)
  • Table 136. Middle East Neurodegenerative Diseases, by Drug Type USD Million (2019-2024)
  • Table 137. Africa Neurodegenerative Diseases, by Application USD Million (2019-2024)
  • Table 138. Africa Neurodegenerative Diseases, by Drug Type USD Million (2019-2024)
  • Table 139. North America Neurodegenerative Diseases, by Country USD Million (2019-2024)
  • Table 140. North America Neurodegenerative Diseases, by Application USD Million (2019-2024)
  • Table 141. North America Neurodegenerative Diseases, by Drug Type USD Million (2019-2024)
  • Table 142. United States Neurodegenerative Diseases, by Application USD Million (2019-2024)
  • Table 143. United States Neurodegenerative Diseases, by Drug Type USD Million (2019-2024)
  • Table 144. Canada Neurodegenerative Diseases, by Application USD Million (2019-2024)
  • Table 145. Canada Neurodegenerative Diseases, by Drug Type USD Million (2019-2024)
  • Table 146. Mexico Neurodegenerative Diseases, by Application USD Million (2019-2024)
  • Table 147. Mexico Neurodegenerative Diseases, by Drug Type USD Million (2019-2024)
  • Table 148. Research Programs/Design for This Report
  • Table 149. Key Data Information from Secondary Sources
  • Table 150. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Neurodegenerative Diseases: by Application USD Million (2013-2018)
  • Figure 5. Global Neurodegenerative Diseases: by Drug Type USD Million (2013-2018)
  • Figure 6. South America Neurodegenerative Diseases Share (%), by Country
  • Figure 7. Asia Pacific Neurodegenerative Diseases Share (%), by Country
  • Figure 8. Europe Neurodegenerative Diseases Share (%), by Country
  • Figure 9. MEA Neurodegenerative Diseases Share (%), by Country
  • Figure 10. North America Neurodegenerative Diseases Share (%), by Country
  • Figure 11. Global Neurodegenerative Diseases share by Players 2018 (%)
  • Figure 12. Global Neurodegenerative Diseases share by Players (Top 3) 2018(%)
  • Figure 13. Global Neurodegenerative Diseases share by Players (Top 5) 2018(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 16. Novartis (Switzerland) Revenue: by Geography 2018
  • Figure 17. Merck Serono (United States) Revenue, Net Income and Gross profit
  • Figure 18. Merck Serono (United States) Revenue: by Geography 2018
  • Figure 19. Teva Pharmaceutical (Isreal) Revenue, Net Income and Gross profit
  • Figure 20. Teva Pharmaceutical (Isreal) Revenue: by Geography 2018
  • Figure 21. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 22. Pfizer (United States) Revenue: by Geography 2018
  • Figure 23. Biogen Idec (United States) Revenue, Net Income and Gross profit
  • Figure 24. Biogen Idec (United States) Revenue: by Geography 2018
  • Figure 25. Bayer Schering Pharma AG (Germany) Revenue, Net Income and Gross profit
  • Figure 26. Bayer Schering Pharma AG (Germany) Revenue: by Geography 2018
  • Figure 27. Boehringer Ingelheim (Germany) Revenue, Net Income and Gross profit
  • Figure 28. Boehringer Ingelheim (Germany) Revenue: by Geography 2018
  • Figure 29. Amarin Corporation (Ireland) Revenue, Net Income and Gross profit
  • Figure 30. Amarin Corporation (Ireland) Revenue: by Geography 2018
  • Figure 31. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 32. AstraZeneca (United Kingdom) Revenue: by Geography 2018
  • Figure 33. Alector (United States) Revenue, Net Income and Gross profit
  • Figure 34. Alector (United States) Revenue: by Geography 2018
  • Figure 35. Yumanity Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 36. Yumanity Therapeutics (United States) Revenue: by Geography 2018
  • Figure 37. Yangtze River Pharmaceutical Group (China) Revenue, Net Income and Gross profit
  • Figure 38. Yangtze River Pharmaceutical Group (China) Revenue: by Geography 2018
  • Figure 39. Chongqing Zein Pharmaceutical (China) Revenue, Net Income and Gross profit
  • Figure 40. Chongqing Zein Pharmaceutical (China) Revenue: by Geography 2018
  • Figure 41. Global Neurodegenerative Diseases: by Application USD Million (2019-2024)
  • Figure 42. Global Neurodegenerative Diseases: by Drug Type USD Million (2019-2024)
  • Figure 43. South America Neurodegenerative Diseases Share (%), by Country
  • Figure 44. Asia Pacific Neurodegenerative Diseases Share (%), by Country
  • Figure 45. Europe Neurodegenerative Diseases Share (%), by Country
  • Figure 46. MEA Neurodegenerative Diseases Share (%), by Country
  • Figure 47. North America Neurodegenerative Diseases Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Novartis (Switzerland)
  • Merck Serono (United States)
  • Teva Pharmaceutical (Isreal)
  • Pfizer (United States)
  • Biogen Idec (United States)
  • Bayer Schering Pharma AG (Germany)
  • Boehringer Ingelheim (Germany)
  • Amarin Corporation (Ireland)
  • AstraZeneca (United Kingdom)
  • Alector (United States)
  • Yumanity Therapeutics (United States)
  • Yangtze River Pharmaceutical Group (China)
  • Chongqing Zein Pharmaceutical (China)
Additional players considered in the study are as follows:
Eisai (Japan) , H.Lundbeck A/S (Denmark) , Jiangsu Hansoh Pharmaceutical (China)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation